[关键词]
[摘要]
目的:对比玻璃体腔注射雷珠单抗联合小功率532激光治疗与单纯532激光治疗对视网膜静脉阻塞(RVO)继发黄斑水肿的疗效。
方法:回顾性研究。选取我科2017-06/2018-03临床确诊的RVO继发黄斑水肿患者48例48眼,其中A组行玻璃体腔注射雷珠单抗联合小功率532激光治疗; B组单纯行532激光正常功率治疗。观察两组患者治疗前和治疗后1、2、3mo时的BCVA、CMT。
结果:A组治疗前、治疗后1、2、3mo时BCVA为0.84±0.02、0.49±0.04、0.29±0.04、0.26±0.04; B组为0.85± 0.04、0.58±0.01、0.53±0.01、0.53±0.02。A组治疗前、治疗后1、2、3mo时CMT分别为527.5±17.59、371±17.36、298.5±32.87、257.75±17.30μm; B组为535±16.36、425±24.44、420.25±17.70、427.75±17.89μm。两组患者治疗后组间比较,A组BCVA和CMT均小于B组(P<0.05)。通过不同时间点与治疗前的组内比较,可知CMT与BCVA数值缓慢下降,以A组治疗后3mo下降最为明显(P<0.05)。
结论:两种方法治疗RVO合并黄斑水肿均有效,视力提高、ME减轻,病情得到有效控制。但联合小功率激光治疗与单纯行532激光组相比,联合组在减轻黄斑水肿、提高视力方面效果更佳。
[Key word]
[Abstract]
AIM: To compare the efficacy of intravitreal injection of ranibizumab plus low power 532 laser versus 532 laser alone for treating retinal vein occlusion(RVO)with macular edema complication.
METHODS: Retrospective study of 48 patients diagnosed RVO complicated with macular edema from June 2017 to March 2018. Group A of 31 eyes(31 patients)were treated with intravitreal injection of ranibizumab plus low power 532 laser(the power is about 2/3 of the power of group B, about 100-130mw), and group B of 17 eyes(17 patients)were treated with 532 laser(the power is 150-200mw)alone. The best corrected visual acuity(BCVA), foveal retinal thickness(CMT), FFA and fundus were observed both before and after treatment at timepoint of 1mo, 2mo and 3mo between the two groups.
RESULTS: In group A, BCVA was 0.84±0.02, 0.49±0.04, 0.29±0.04, 0.26±0.04 before and the 1, 2, 3mo after treatment. In group B, BCVA was 0.85±0.04, 0.58±0.01, 0.53±0.01, 0.53±0.02. The CMT value of group A before and after treatment was 527.5±17.59, 371±17.36, 298.5±32.87, 257.75±17.30μm, respectively. Group B was 535±16.36, 425±24.44, 420.25±17.70, 427.75±17.89μm. Intra-group comparison show statistical differences, group A had lower BCVA and CMT value than group B at the same time point(P<0.05). Inter-group comparison with pre-treatment, there was significant difference in BCVA between 1mo, 2mo and 3mo after treatment(P<0.05). The CMT and BCVA value from group A are the lowest.
CONCLUSION: Both methods are effective in treating RVO with macular edema, improving vision, alleviating ME, and effectively controlling the disease.However, combined treatment can significantly reduce macular edema, improve vision, and be more stable than laser treatment alone.
[中图分类号]
[基金项目]